Sandwich ELISA, HRP-labelled antibody
Plasma-EDTA, Amniotic fluid, Cell culture supernatant
Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).
Limit of Detection
n = 8; CV = 4.2%
n = 11; CV = 7.0%
- It is intended for research use only
- The total assay time is about 20 hours
- The kit measures shedded HLA-G1 and HLA-G5 in EDTA plasma, amniotic fluid, or cell culture supernatant
- Calibrator is human native protein
- Assay format is 96 wells
- Components of the kit are provided ready to use, concentrated or lyophilized
Immune Response, Infection and Inflammation, Reproduction, Transplantation
HLA-G differs from the other MHC class I genes by its low polymorphism and alternative splicing that generates seven HLA-G proteins, whose tissue-distribution is restricted to normal fetal and adult tissues that display a tolerogeneic function toward both innate and acquired immune cells. Soluble HLA-G is an immunosuppressive molecule inducing apoptosis of activated CD8(+) T cells and down-modulating CD4(+) T cell proliferation. Recently, using specific ELISA to analyse the presence of sHLA-G molecules in culture supernatants of early embryos obtained by in vitro fertilization (IVF) before transfer, several reports demonstrated that positive embryo implantations occurred with embryo secreting sHLA-G molecules. These breakthrough results indicate that sHLA-G ELISA can be a useful biochemical assay in addition to embryo morphology in embryo selection for transfer in IVF treatment if there are other embryos with the same morphology. Furthermore, monitoring of sHLA-G in amniotic fluid and plasma of pregnant women may have an important prognostic value to recognize pathological situations. Other interesting observations suggest that HLA-G molecules seem to be directly involved in transplant acceptation, and their analysis should be taken into consideration when monitoring transplant-patients status. In addition, soluble HLA-G plasma levels are increased in lyphoproliferative disorders or in patients suffering from malignant melanoma, glioma, breast and ovarian cancer.